Eli Lilly may drop inhaled insulin plan

Mar 10, 2008

Eli Lilly and Co. has pulled the plug on a collaboration with a Massachusetts company to develop inhaled insulin for diabetics.

Alkermes Inc. said it received a letter Friday from Lilly terminating the development and license agreement for AIR Inhaled Insulin. The announcement was made shortly after Alkermes released a statement that Lilly was evaluating its business case for the drug.

AIR Insulin is being evaluated in a broad phase-3 clinical trial program with patients with type 1 and type 2 diabetes. Alkermes said it was not aware of any safety, efficacy or manufacturing issues that would lead to the termination of the agreement.

Copyright 2008 by United Press International

Explore further: Emergency department opioid prescribing

Related Stories

Recommended for you

China to lift price controls on most drugs starting June 1

9 hours ago

Chinese regulators will lift price controls on most pharmaceutical drugs starting June 1 in hopes that the market-driven pricing system will keep medical costs in check, the National Development and Reform Commission announced ...

Emergency department opioid prescribing

May 04, 2015

The Emergency Department (ED) is at the convergence of the opioid epidemic as emergency physicians (EPs) routinely care for patients with adverse effects from opioids, including overdoses and those battling addiction, as ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.